TasWeekend – In the Business of Hope
29/05/2023
Groundbreaking work, through a series of cutting-edge clinical trials, being undertaken by two of the state’s leading cancer specialists, Louise Nott and Michael Jones, is
0
Trials
0
Sites
0
+
Patients Enrolled
0
Countries
What we do
ANZUP is the leading cancer cooperative clinical trials group that brings together all of the professional disciplines and groups involved in researching and treating below the belt (penile, bladder, kidney, prostate and testicular) cancers and conduct high quality clinical research.
ANZUP identifies gaps in evidence and areas of clinical need,
collaborates with the leading clinicians and researchers in below the
belt cancers, and communicate frequently and effectively with the
broader community along the way.
Telehealth and Teletrials
Teletrials builds on the telehealth model and increases access to clinical trials for people with cancer living in rural and remote locations.
Teleheath and Teletrials
Teletrials builds on the telehealth model and increases access to clinical trials for people with cancer living in rural and remote locations, or in self-isolation due to COVID-19. Teletrials also allows trials recruitment and activity to continue.
Latest News
New Clinical Trial for Personalised Adaptive Treatment of Prostate Cancer Enrolls First Participants
28/02/2023
A randomised clinical trial aiming to improve survival in advanced prostate cancer by adapting treatment with a personalized dosing strategy has enrolled its first participants.
ANZUP’s Pain-free TRUS B trial wins the BJUI Global Prize 2023 for article of the year
28/02/2023
Dickon Hayne accepted the BJUI Global Prize for 2023 for the Pain-Free TRUS B article that featured in BJUI in 2022, at the USANZ meeting
PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [¹⁷⁷Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial
24/10/2022
PSMA and FDG-PET as predictive and prognostic biomarkers TheraP biomarker Oct 2022 (1)Previously, results from the TheraP trial showed that treatment with lutetium-177 [¹⁷⁷Lu]Lu-PSMA-617 improved
TasWeekend – In the Business of Hope
29/05/2023
Groundbreaking work, through a series of cutting-edge clinical trials, being undertaken by two of the state’s leading cancer specialists, Louise Nott and Michael Jones, is
New Clinical Trial for Personalised Adaptive Treatment of Prostate Cancer Enrolls First Participants
28/02/2023
A randomised clinical trial aiming to improve survival in advanced prostate cancer by adapting treatment with a personalized dosing strategy has enrolled its first participants.
ANZUP’s Pain-free TRUS B trial wins the BJUI Global Prize 2023 for article of the year
28/02/2023
Dickon Hayne accepted the BJUI Global Prize for 2023 for the Pain-Free TRUS B article that featured in BJUI in 2022, at the USANZ meeting